文献速递免疫规划妇幼与学校卫生

孕期接种破伤风-白喉-无细胞百日咳疫苗预防婴儿百日咳的效果

Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis.
PubMed 文献 · Vaccine · 2023-04-07

基于美国CDC与EIP网络2011至2014年数据,采用病例对照研究评估孕期接种含五种百日咳组分的Tdap5疫苗对不足2月龄婴儿百日咳的预防效果。研究纳入160例婴儿百日咳病例和302名匹配对照,结果显示孕27至36周接种Tdap5的疫苗有效性为92.5%(95%CI 38.5%-99.1%)。

要点

  • 孕27至36周接种Tdap5对不足2月龄婴儿百日咳的有效性为92.5%(95%CI 38.5%-99.1%)
  • 孕期未接种而产后接种或分娩前不足14天接种不能保护婴儿免患百日咳
  • 因匹配病例与对照间缺乏不一致性,无法计算Tdap5对百日咳相关住院的有效性

核心结论

  • 孕27至36周接种Tdap5对保护低龄婴儿免患百日咳高度有效。

研究设计与样本

  • 美国CDC与新发感染计划(EIP)网络合作开展的病例对照研究,基于EIP网络2011至2014年收集的数据,使用该数据集进行Tdap5产品特异性疫苗有效性分析。
  • 研究纳入160例婴儿百日咳病例和302名匹配对照。

主要发现

  • 孕27至36周接种Tdap5预防婴儿百日咳的有效性为92.5%(95%CI 38.5%-99.1%)。
  • 孕27至36周接种Tdap5对百日咳相关住院的有效性因匹配病例与对照间缺乏不一致性而无法计算。
  • 产后接种或分娩前不足14天接种不能保护婴儿免患百日咳。

关键数值与推荐

  • 主要结局为孕27至36周接种Tdap5者所生婴儿的疫苗有效性,该时段符合美国免疫实践咨询委员会推荐的孕期Tdap接种理想时机。
  • OR及95%CI采用条件logistic回归估计,疫苗有效性按(1-OR)×100%计算。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine containing five pertussis components (Tdap5; Adacel®, Sanofi) when given during pregnancy at preventing pertussis in infants less than 2 months of age. METHODS: The US Centers for Disease Control and Prevention (CDC), in collaboration with the Emerging Infections Program (EIP) Network, undertook a case-control study evaluating the effectiveness of Tdap vaccination in pregnancy against pertussis in infants less than 2 months of age based on data collected by the EIP Network from 2011 through 2014. The dataset from the CDC/EIP Network study was used to conduct this product-specific vaccine effectiveness analysis of Tdap5 vaccination in pregnancy to prevent disease in young infants. The main outcome of interest was vaccine effectiveness in infants whose pregnant parents were vaccinated with Tdap5 between 27 and 36 weeks' gestation, in accordance with the ideal timing for Tdap vaccination in pregnancy recommended by the US Advisory Committee on Immunization Practices. Odd ratios (ORs) and 95 % confidence intervals (CIs) were estimated using conditional logistic regression, and vaccine effectiveness was calculated as (1-OR) × 100 %. RESULTS: There were 160 infant pertussis cases and 302 matched controls included in this Tdap5-specific study. Tdap5 effectiveness in preventing pertussis in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation was 92.5 % (95 % CI, 38.5 %-99.1 %). Effectiveness of Tdap5 against pertussis-related hospitalization in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation could not be calculated due to lack of discordance among matched cases and controls. Vaccination of the parents after pregnancy or less than 14 days before delivery did not protect infants from pertussis. CONCLUSIONS: Tdap5 vaccination in pregnancy between 27 and 36 weeks' gestation is highly effective at protecting young infants from pertussis. STUDY REGISTRATION: ClinicalTrials.gov, NCT05040802.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vargas-Zambrano JC, Clark LR, Johnson DR, et al. Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis. Vaccine. 2023. PMID: 37032227. doi:10.1016/j.vaccine.2023.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。